Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATION151767-02-1//file1.lookchem.com/cas/reactions/2021/07/02/7617467.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

151767-02-1 CAS NO.151767-02-1

Min.Order Quantity:
100 Kilogram
Purity:
99%
Port:
China Main Port
Payment Terms:
L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • RARECHEM AH PB 0251
  • 151767-02-1
  • C35H35ClNNaO3S

Quick Details

  • ProName: 151767-02-1
  • CasNo: 151767-02-1
  • Molecular Formula: C35H35ClNNaO3S
  • Appearance: powder
  • Application: 151767-02-1
  • DeliveryTime: Within 3-7 days
  • PackAge: Depended
  • Port: China Main Port
  • ProductionCapacity: 300 Kilogram/Month
  • Purity: 99%
  • Storage: Refrigerator
  • Transportation: by air or by sea
  • LimitNum: 100 Kilogram
  • Valid Period: 6 month
  • Application: Multipurpose intermediate
  • Application: ISO/9001 Certificate

Superiority

montelukast sodium basic information
pharmacological effect application
product name: montelukast sodium
synonyms: singulair;montelukast na;montelukast sodium;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;mk-476, singulair;montelukast, sodium salt
cas: 151767-02-1
mf: c35h35clnnao3s
mw: 608.17
einecs:
product categories: active pharmaceutical ingredients;apis;chiral reagents;intermediates & fine chemicals;pharmaceuticals;sulfur & selenium compounds;isotope labeled compounds;pharmaceutical intermediates;dioxyline;other apis;inhibitors
mol file: 151767-02-1.mol
montelukast sodium structure
montelukast sodium chemical properties
storage temp. -20°c freezer, under inert atmosphere
safety information
hazard codes xi
risk statements 63-41-62
safety statements 26
msds information
montelukast sodium usage and synthesis
pharmacological effect cysteinyl leukotrienes (ltc4, ltd4, lte4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. these important asthma pre-inflammatory mediators can bind to the cysteinyl leukotriene receptors (cyslt) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation.
montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. it was successfully developed by the merck company (german) and had entered into market in canada, finland, and mexican in 1997. it is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment.
montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. it is also a potent oral preparation that can significantly improve the inflammatory indicators. biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the cyslt1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β- adrenergic receptors). montelukast can effectively suppress the physiological effects caused by the binding between ltc4, ltd4 and lte4 receptor and cyslt1 receptor without any receptor agonistic activity. there is the secondary type of cysteinyl leukotriene receptor (cyslt2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. so far, researchers haven’t cloned two receptors so the situation of cyslt receptor is illustrated through binding assay and pharmacological analysis. it has been now thought that montelukast does not antagonize cyslt2 receptors.
the above information is edited by the chemicalbook of dai xiongfeng.
application it can be applied to alleviate the symptoms caused by allergic rhinitis.
usage a selective leukotriene d4-receptor antagonist. used as an antiasthmatic
usage antiinfective
usage a potent and highly selective cyslt1 receptor antagonist, without demonstrated cyslt2 activity

service we provide:

1. mixed container, we can mix different items in one container.

2. quality control, before shipment, free sample for test. after shipment, keep sample for 3 years

3. prompt shipment with professional documents

4. packing as your request, with photo before shipment

Details

  • exhibition in shanghai

we have clients throughout the world:

professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

our laboratoy

we have our own independent lab test center:

this makes sure that our technology support is reliable and authoritative.all of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.

our factory

high quality with competitive price:

we are manufacturer and can provide high quality products with factory price

package & shipment

fast and safe delivery:

parcels can be sent out within 24 hours after payment. tracking number is available

secure and discreet shipment. you have various choices of transportation methods

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)